Author pages are created from data sourced from our academic publisher partnerships and public sources.
Share This Author
Bacterial biofilms in nature and disease.
The National Institutes of Health chronic prostatitis symptom index: Development and validation of a new outcome measure
A psychometrically valid index of symptoms and quality of life impact for men with chronic prostatitis is developed, which is poorly defined, poorly understood, poorly treated and bothersome. Expand
NIH consensus definition and classification of prostatitis.
Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia.
Dutasteride is a potent inhibitor of dihydrotestosterone production that is safe and effective in terms of the reduction of prostate volume and symptoms, flow rate improvement, and the reduction the risk of acute urinary retention and surgery during a 24-month study period. Expand
Prevalence of prostatitis-like symptoms in a population based study using the National Institutes of Health chronic prostatitis symptom index.
This community based study using the new prostatitis symptom index confirms that chronic prost atitis-like symptoms are common among men at risk in a communitybased study. Expand
The relationship between prostate inflammation and lower urinary tract symptoms: examination of baseline data from the REDUCE trial.
- J. Nickel, C. Roehrborn, M. O'Leary, D. Bostwick, M. Somerville, R. Rittmaster
- European urology
- 1 December 2008
In the REDUCE population, there is evidence of a relationship between the degree of LUTS and the level of chronic inflammation, and more severe inflammation was associated with higher IPSS scores. Expand
The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group.
- J. Mcconnell, R. Bruskewitz, +9 authors J. Waldstreicher
- The New England journal of medicine
- 1 July 1998
Among men with symptoms of urinary obstruction and prostatic enlargement, treatment with finasteride for four years reduces symptoms and prostate volume, increases the urinary flow rate, and reduces the risk of surgery and acute urinary retention. Expand
Tobramycin resistance of Pseudomonas aeruginosa cells growing as a biofilm on urinary catheter material
- J. Nickel, I. Ruseska, J. B. Wright, J. Costerton
- Biology, Medicine
- Antimicrobial Agents and Chemotherapy
- 1 April 1985
Data indicate that growth within thick adherent biofilms confers a measure of tobramycin resistance on cells of P. aeruginosa. Expand
Inflammation and benign prostatic hyperplasia.
- J. Nickel
- The Urologic clinics of North America
- 1 February 2008
The interrelationships between prostate-associated histologic and clinical conditions and their impact on the management of benign prostatic hyperplasia are described. Expand
The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia
Among men with symptoms of urinary obstruction and prostatic enlargement, treatment with finasteride for four years reduces symptoms and prostate volume, increases the urinary flow rate, and reduces the probability of surgery and acute urinary retention. Expand